CX Institutional’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$515K Buy
5,971
+74
+1% +$6.58K 0.01% 463
2026
Q2
$533K Buy
5,897
+631
+12% +$52.9K 0.02% 463
2026
Q1
$422K Buy
5,266
+728
+16% +$60K 0.01% 507
2025
Q4
$387K Buy
4,538
+218
+5% +$17.9K 0.01% 497
2025
Q3
$336K Buy
4,320
+6
+0.1% +$469 0.01% 535
2025
Q2
$337K Buy
4,314
+416
+11% +$31K 0.01% 470
2025
Q1
$283K Sell
3,898
-70
-2% -$5.01K 0.01% 496
2024
Q4
$294K Buy
+3,968
New +$278K 0.01% 450
2024
Q3
– Sell
-3,775
Closed -$349K – 562
2024
Q2
$349K Sell
3,775
-38
-1% -$3.36K 0.02% 425
2024
Q1
$364K Buy
3,813
+1,240
+48% +$104K 0.02% 417
2023
Q4
$196K Sell
2,573
-1,059
-29% -$73.7K 0.01% 492
2023
Q3
$252K Sell
3,632
-885
-20% -$71.1K 0.01% 437
2023
Q2
$426K Buy
4,517
+131
+3% +$11.4K 0.02% 365
2023
Q1
$361K Buy
4,386
+434
+11% +$34.1K 0.02% 386
2022
Q4
$295K Buy
+3,952
New +$305K 0.02% 431
2022
Q3
– Sell
-1,212
Closed -$115K – 683
2022
Q2
$115K Buy
+1,212
New +$125K 0.01% 532
2021
Q4
– Sell
-1,243
Closed -$141K – 519
2021
Q3
$141K Buy
1,243
+89
+8% +$10.2K 0.01% 396
2021
Q2
$120K Buy
1,154
+409
+55% +$38.6K 0.01% 409
2021
Q1
$62K Sell
745
-57
-7% -$4.82K 0.01% 451
2020
Q4
$73K Buy
802
+269
+50% +$22.3K 0.01% 396
2020
Q3
$43K Buy
533
+211
+66% +$16.5K ﹤0.01% 409
2020
Q2
$22K Buy
322
+82
+34% +$5.83K ﹤0.01% 420
2020
Q1
$15K Buy
240
+90
+60% +$6.49K ﹤0.01% 411
2019
Q4
$12K Hold
150
– – ﹤0.01% 408
2019
Q3
$11K Buy
150
+12
+9% +$843 ﹤0.01% 449
2019
Q2
$8K Hold
138
– – ﹤0.01% 523
2019
Q1
$9K Buy
138
+111
+411% +$6.34K ﹤0.01% 470
2018
Q4
$1K Buy
+27
New +$1.37K ﹤0.01% 491

Other funds holding EW

CX Institutional's EW Position: Q3 2026 in Review

CX Institutional increased its Edwards Lifesciences (EW) stake by 1.3% in Q3 2026, buying an estimated $6.58K and bringing the position to 5,971 shares worth $515K. The position accounts for 0.01% of the portfolio, ranked #463.

CX Institutional first reported a position in EW in Q4 2018 and has held it in 28 quarters since. The position peaked at $533K in Q2 2026. 326 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • CX Institutional held 5,971 shares of Edwards Lifesciences worth $515K as of Q3 2026.
  • CX Institutional bought 74 Edwards Lifesciences shares in Q3 2026, an estimated $6.58K.
  • Edwards Lifesciences made up 0.01% of CX Institutional's portfolio in Q3 2026, its #463 holding.
  • CX Institutional first reported a position in Edwards Lifesciences in Q4 2018 and has held it in 28 quarters since.
  • CX Institutional's Edwards Lifesciences position peaked at $533K in Q2 2026.
  • 326 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.